Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

34.24 -0.06 (-0.17%)
Official Closing Price Updated: 4:15 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Short Volatility Alert: Legend Biotech Corporation
On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went up +6.97% to $51.10. The... 
Via Benzinga
Legend Biotech Shares Move Higher After Bullish BMO Pitch
Via Benzinga
Short Volatility Alert: Legend Biotech Corporation
On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went down -1.38% to $42.96. The... 
Via Benzinga
How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer
This biotech stock launched in February to work on CAR-T treatments. 
Via Investor's Business Daily
Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma
From Legend Biotech
Via Business Wire
Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers
From Legend Biotech
Via Business Wire
Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights
From Legend Biotech
Via Business Wire
Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Legend Biotech
Via Business Wire
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and... 
Via Talk Markets
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
From Legend Biotech
Via Business Wire
Legend Biotech Appoints Lori Macomber as Chief Financial Officer
From Legend Biotech
Via Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
HFCAA News: 128 Chinese Stocks the SEC Could Delist
The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news. 
Via InvestorPlace
Legend Biotech Announces Appointment of Global Head of Research and Early Development
From Legend Biotech Corporation
Via Business Wire
Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework
Via Benzinga
EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy
The European Medicines Agency's CHMP  
Via Benzinga
CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
Flanders Investment and Trade Names Legend Biotech Newcomer of the Year
From Legend Biotech
Via Business Wire
Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
From Legend Biotech
Via Business Wire
Analyst Ratings For Legend Biotech
Analysts have provided the following ratings for Legend Biotech (NASDAQ:LEGN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million.... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi
Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in... 
Via Talk Markets
GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment
Key takeaways: GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% of that Legend Biotech’s Cilta-cel CAR-T... 
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy
The FDA has approved Legend Biotech Corporation's (NASDAQ: LEGN) first product, Carvykti (ciltacabtagene autoleucel; cilta-cel), for relapsed or refractory... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.